{"id":61877,"title":"Older patients with chronic myeloid leukemia (?65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.","abstract":"","date":"2014-07-17","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24658964","annotations":[{"name":"Imatinib","weight":0.402244,"wikipedia_article":"http://en.wikipedia.org/wiki/Imatinib"},{"name":"Intravenous therapy","weight":0.368006,"wikipedia_article":"http://en.wikipedia.org/wiki/Intravenous_therapy"},{"name":"Leukemia","weight":0.0972222,"wikipedia_article":"http://en.wikipedia.org/wiki/Leukemia"},{"name":"Chronic myelogenous leukemia","weight":0.0972222,"wikipedia_article":"http://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia"},{"name":"Chronic (medicine)","weight":0.0604488,"wikipedia_article":"http://en.wikipedia.org/wiki/Chronic_(medicine)"},{"name":"Myeloid","weight":0.0546925,"wikipedia_article":"http://en.wikipedia.org/wiki/Myeloid"},{"name":"Old age","weight":0.0279596,"wikipedia_article":"http://en.wikipedia.org/wiki/Old_age"},{"name":"Randomized controlled trial","weight":0.0180213,"wikipedia_article":"http://en.wikipedia.org/wiki/Randomized_controlled_trial"}]}
